Does Dr. LIYA BEYDERMAN have financial conflicts of interest?

Dr. LIYA BEYDERMAN (MD) has received a total of $1,792 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $1,792 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. LIYA BEYDERMAN?

According to CMS Open Payments data, Dr. LIYA BEYDERMAN received funding from SUPERNUS PHARMACEUTICALS ($876), TRIS PHARMA ($529), and GREENWICH BIOSCIENCES ($132).

Does Dr. LIYA BEYDERMAN receive research grants or speaking fees?

Dr. LIYA BEYDERMAN has received $1,792 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. LIYA BEYDERMAN

MDReal-Time Hydrated

Specialty: Psychiatry & Neurology, Neurology with Special Qualifications in Child Neurology

Practice Location: CHARLOTTE, NC 28210

NPI Number: 1699816017

LIFETIME INDUSTRY VALUE

$1,792

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. BEYDERMAN is a verified Psychiatry & Neurology, Neurology with Special Qualifications in Child Neurology practitioner based in CHARLOTTE, NC.

Between 2021 and 2025, Dr. BEYDERMAN had an overall industry promotional and research financial footprint of $1,792 as recorded in the federal CMS Open Payments database.

$1,792 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. BEYDERMAN's primary funding source is SUPERNUS PHARMACEUTICALS, which accounts for $876 (representing 48.9% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

SUPERNUS PHARMACEUTICALS

Rank 1

$876

48.9%

TRIS PHARMA

Rank 2

$529

29.5%

GREENWICH BIOSCIENCES

Rank 3

$132

7.4%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.